Transforming Prostate Cancer Treatment

Prostate cancer is the most commonly diagnosed cancer in Australian men, with approximately 25,500 new cases in Australia each year.

Cabrini is one of the leading hospitals in Australia for the diagnosis and treatment of prostate cancer*. At Cabrini, we treat 700 prostate cancer patients each year, representing 13% of all cases in Victoria.

Professor Mark Frydenberg AM, Head of Cabrini Department of Urology, said: “Together with my team of specialist researchers and in collaboration with the Prostate Cancer Research Group Lab at Monash University, our vision is to empower breakthroughs to improve the survival and quality of life for patients with prostate cancer.”

A/Professor Weranja Ranasinghe, Cabrini Department of Urology was awarded the 2024 Auric Innovation Grant, made possible by donors Mrs Lee and Mr Brian Johnstone. A/P Ranasinghe aims to expand access to radioligand therapy for prostate cancer patients, allowing more patients to access the latest treatment methods.

“The complexity of prostate cancer tumours is a key contributor to why some treatments fail. To overcome this, the Cabrini Department of Urology established the MURAL Collection: a library of xenograft models that have been developed using tumour samples collected from patients treated at Cabrini. Capturing the broad biological diversity of prostate cancer, the MURAL Collection is a critical resource for both the Australian and global prostate cancer research landscape,” A/P Ranasinghe shared.

This program enables patients to access the newest innovations in prostate cancer treatment while also attracting leading specialist urologists to Cabrini, elevating the standard of care delivered to all patients.

This research is only possible with donations from far sighted donors who understand that investing in research now, pays off in the future.

‍